Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Tarlock

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Blood Advances|September 23, 2022
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugateThao Tang, Quy Le, Sommer Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2017
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Michael R Loken, et al.
Blood|November 8, 2019
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacyRebecca A Gardner, Francesco Ceppi, Julie Rivers, et al.
Transplantation and Cellular Therapy|December 7, 2025
Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid MalignanciesEmily C Merkel, Ted Gooley, Monica S Thakar, et al.
Blood Advances|May 12, 2026
Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexityJohn N Colgan, Jack H Peplinski, Yi-Cheng Wang, et al.
Pediatric Blood & Cancer|February 10, 2015
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemiaKatherine Tarlock, Bill Chang, Todd Cooper, et al.
Oncotarget|June 15, 2018
Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profilingKatherine Tarlock, Shan Zhong, Yuting He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Blood Advances|January 3, 2023
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemiaQuy Le, Thao Tang, Amanda Leonti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaQuy Le, Sommer Castro, Thao Tang, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Blood Advances|September 23, 2022
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugateThao Tang, Quy Le, Sommer Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2017
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Michael R Loken, et al.
Blood|November 8, 2019
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacyRebecca A Gardner, Francesco Ceppi, Julie Rivers, et al.
Transplantation and Cellular Therapy|December 7, 2025
Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid MalignanciesEmily C Merkel, Ted Gooley, Monica S Thakar, et al.
Blood Advances|May 12, 2026
Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexityJohn N Colgan, Jack H Peplinski, Yi-Cheng Wang, et al.
Pediatric Blood & Cancer|February 10, 2015
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemiaKatherine Tarlock, Bill Chang, Todd Cooper, et al.
Oncotarget|June 15, 2018
Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profilingKatherine Tarlock, Shan Zhong, Yuting He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Blood Advances|January 3, 2023
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemiaQuy Le, Thao Tang, Amanda Leonti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaQuy Le, Sommer Castro, Thao Tang, et al.
Pageof 5